Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deulorlatinib in Advanced ALK-positive NSCLC After 2nd-Gen ALK Inhibitors
NCT05955391Phase 2Active, not recruiting
- Sponsor
- Shenzhen TargetRx
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deulorlatinib in non-small cell lung cancer (NSCLC), sponsored by Shenzhen TargetRx. Primary endpoint: Objective Response Rate. Started Jan 2023; status: active, not recruiting.
02
Drugs
deulorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05955391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05955391.